<DOC>
	<DOC>NCT02574078</DOC>
	<brief_summary>The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.</brief_summary>
	<brief_title>A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description>Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) **Please note that the study is no longer enrolling patients for Groups A, B, C, and E.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histologically confirmed locally advanced or stage IV NSCLC Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 02 Tumor tissue sections must be available for biomarker evaluation Untreated or active/progressing Central Nervous system (CNS) metastases Active, known or suspected autoimmune disease Known history of testing positive for HIV or AIDS Active or chronic infection of hepatitis B virus or hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>